Alkermes Breaks $1 Billion

Alkermes (NASDAQ: ALKS) had 2018 revenue that came in at over $1 billion, the level that's typically set as a blockbuster.

Of course, it took the biotech a couple of drugs and royalties on a handful of others to get to that level, but it's a solid start as the company continues to transition from a formulation company to one with gro